Moderna, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Moderna, Inc. stock analysis MRNA overview
Somewhat Bearish -25

Moderna (MRNA) Stock Declines While Market Improves: Some Information for Investors

📉 Moderna stock declined -1.54% to close at $51.30, lagging the broader market gains for the S&P 500 and Nasdaq.

📅 Over the past month, MRNA shares depreciated 6.91%, significantly underperforming both the Medical sector and the S&P 500.

🔍 Investors are awaiting quarterly earnings reports, with consensus EPS projected at -$2.03, a 19.44% increase year-over-year.

💰 Revenue for the upcoming quarter is forecast to hit $229.96 million, representing substantial 112.92% growth compared to last year.

📈 Full-year earnings are currently estimated at -$6.8 per share with revenue of $2.08 billion, showing positive trends in projected figures.

👀 Analyst estimates have shifted positively over the past month, which historically correlates with improved stock price performance.

⚖️ Moderna currently holds a Zacks Rank of #3 (Hold), while its EPS estimate has risen 1.46% recently.

🏥 The company operates within the Medical - Biomedical and Genetics industry, which ranks in the bottom 41% of all tracked industries.

📊 Top-rated industries historically outperform lower-rated groups by a factor of 2 to 1 based on Zacks research data.

🔮 Long-term data suggests that Zacks Rank #1 stocks have delivered an average annual return of +25% since 1988.

Bullish Signals
  • Moderna's projected quarterly earnings per share are expected to be -$2.03, representing a 19.44% increase compared to the same quarter of the previous year.
  • Projected revenue for the upcoming quarter is forecast at $229.96 million, indicating a significant 112.92% growth compared to the corresponding quarter of the prior year.
  • Zacks Consensus Estimates predict full-year revenue of $2.08 billion with a +7.12% increase from the former year.
  • The Zacks Consensus EPS estimate has moved 1.46% higher within the past month, signaling potential positive shifts in analyst expectations.
  • Moderna's Zacks Rank is #3 (Hold), while its industry peers are evaluated against a rank of #5 or worse for strong outperformance opportunities.
Risk Factors
  • Moderna's stock price lags significantly behind the broader market, declining 1.54% on a day when the S&P 500 gained 0.62%, and underperforming over the past month with a 6.91% drop compared to a market gain.
  • The company currently holds a Zacks Rank of #3 (Hold), which is positioned in the middle of the rating scale rather than indicating strong buy or growth potential.
  • Moderna operates within an industry with a Zacks Industry Rank of 144, placing it in the bottom 41% of all rated industries compared to peers.
  • Consensus estimates project earnings of -$6.8 per share for the fiscal year, indicating continued losses rather than profitability growth.
  • The stock has depreciated 6.91% over the past month while the broader market and Medical sector saw more moderate declines or gains.
Full Analysis
Moderna Inc. (MRNA) stock closed at $51.30, representing a 1.54% decline and significantly underperforming the broader market, where the S&P 500 gained 0.62%, the Dow Jones Industrial Average rose 0.58%, and the Nasdaq added 0.83%. Over the past month, MRNA shares have depreciated by 6.91%, further lagging behind the Medical sector's loss of 3.18% and the S&P 500's overall gain of 0.8%. Investors are now focusing on the company's upcoming earnings report, where analysts project an earnings per share (EPS) of -$2.03, reflecting a 19.44% improvement from the same quarter last year. Revenue forecasts for the recent quarter stand at $229.96 million, marking a substantial 112.92% increase compared to the prior-year equivalent. On an annual basis, Zacks Consensus Estimates anticipate total earnings of -$6.8 per share and revenue of $2.08 billion, with projected year-over-year changes of +6.34% and +7.12%, respectively. Recent analyst estimate revisions are under scrutiny as they often correlate with stock price performance, suggesting positive outlooks can signal potential upside for investors monitoring near-term business trends. According to the Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), Moderna currently holds a Zacks Rank of #3 (Hold). This rating is based on recent consensus EPS estimates that have moved 1.46% higher over the past month. Industry analysis indicates that the Medical - Biomedical and Genetics industry ranks in the bottom 41% among more than 250 industries, with research showing that top-rated industries generally outperform the bottom half by a factor of 2 to 1. The article notes the historical track record of the Zacks Rank, stating that #1 stocks have contributed an average annual return of +25% since 1988, while also mentioning a free report offering 7 best stocks for the next 30 days available through Zacks Investment Research.